Protagonist Therapeutics Q3 revenue surges on Takeda payments
PTGX•Protagonist Therapeutics reported $274.41 million in third-quarter license and collaboration revenue, driven mainly by $200 million in Takeda opt-out fees and a $75 million milestone payment. The company reported $220.02 million in net income and authorized a $300 million share buyback.
1. Revenue and earnings
Third-quarter license and collaboration revenue was $274.41 million, primarily driven by a $200 million opt-out fee and a $75 million milestone payment from Takeda after FDA approval of MIMRYLO. Protagonist Therapeutics reported net income of $220.02 million, diluted EPS of $3.07 and operating expenses of $56.08 million.
2. Plans and spending
The company authorized a $300 million share buyback program. It expects research and development expenses to rise in late 2026 as clinical programs advance, plans to start a Phase 2b study of PN-881 in plaque psoriasis in early Q1 2027, and expects to begin a Phase 1 study of oral PN-477o in the first half of 2027.




